Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users

PURPOSE/BACKGROUND: As part of a human abuse potential (HAP) study of lemborexant (LEM), the effects of therapeutic (LEM 10 mg), and supratherapeutic doses of LEM 20 mg and LEM 30 mg on cognition and psychomotor performance were compared with placebo (PBO) and supratherapeutic doses of zolpidem (ZOL...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Hall, Nancy, Alur, Jagadeesh, Filippov, Gleb, Reyderman, Larisa, Setnik, Beatrice, Henningfield, Jack, Moline, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257063/
https://www.ncbi.nlm.nih.gov/pubmed/35748777
http://dx.doi.org/10.1097/JCP.0000000000001562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257063/
https://www.ncbi.nlm.nih.gov/pubmed/35748777
http://dx.doi.org/10.1097/JCP.0000000000001562

Ejemplares similares